Hydroxyzine vs. Benzodiazepines for Post-Injury Anxiety: Clinical Comparison

James Wong — Founder & Pharmacist, LienScripts | February 13, 2026 | 7 min read

A clinical comparison of hydroxyzine and benzodiazepines for treating post-injury anxiety, PTSD, and insomnia. Understand addiction risk, DEA scheduling, opioid co-prescribing concerns, and how pharmacy liens cover both.

Post-Injury Anxiety, PTSD, and Insomnia: A Pharmacological Challenge

Physical injuries from accidents, assaults, or workplace incidents are frequently accompanied by significant psychological sequelae. Anxiety disorders, post-traumatic stress disorder (PTSD), and sleep disturbances are common in personal injury patients — and they require treatment just as much as fractures or soft tissue injuries. Two medication classes appear regularly in PI prescribing for these conditions: hydroxyzine (a non-controlled antihistamine with anxiolytic properties) and benzodiazepines (Schedule IV controlled substances including clonazepam, lorazepam, and diazepam).

This article provides a clinical comparison of these approaches to help patients, attorneys, and treating physicians understand the clinical rationale behind each choice — and how pharmacy liens support access to both.

Hydroxyzine: Mechanism and Classification

Hydroxyzine is a first-generation H1 antihistamine with anxiolytic, antipruritic, and mild sedative properties. Its anxiolytic effect is mediated primarily through H1 receptor antagonism in the central nervous system, though it also has activity at muscarinic receptors and serotonin receptors. Importantly, hydroxyzine is not a controlled substance — it has no DEA schedule, no abuse potential classification, and no federal prescribing restrictions.

Hydroxyzine is available in two salt forms: hydroxyzine hydrochloride (Atarax) and hydroxyzine pamoate (Vistaril). Both are clinically equivalent for anxiety and sleep indications, though hydroxyzine pamoate is somewhat more commonly prescribed for insomnia given its slightly more sedating profile at equivalent doses. Typical anxiolytic dosing is 25-50 mg up to four times daily; for insomnia or procedural sedation, doses of 50-100 mg are common.

Benzodiazepines: Mechanism and Classification

Benzodiazepines (BZDs) enhance the effect of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. By binding to the GABA-A receptor complex, benzodiazepines increase chloride ion channel opening frequency, producing CNS depression that manifests as anxiolysis, sedation, muscle relaxation, and anticonvulsant effects.

Common benzodiazepines prescribed in PI settings for anxiety, PTSD, and insomnia include:

• Clonazepam (Klonopin) — long-acting, often used for chronic anxiety
• Lorazepam (Ativan) — intermediate-acting, often used for acute anxiety
• Diazepam (Valium) — long-acting, used for anxiety and muscle spasm
• Alprazolam (Xanax) — short-acting, used for acute anxiety episodes

All benzodiazepines are DEA Schedule IV controlled substances.

[!SOURCE] FDA drug approvals and scheduling: hydroxyzine HCl NDA 008693; clonazepam NDA 017533 (Schedule IV). Benzodiazepine dependence and withdrawal: Lader M, Lancet 2011;378:73-74. PMID: 21683900.

Addiction Risk and DEA Scheduling

The addiction and dependence profiles of hydroxyzine and benzodiazepines differ fundamentally — a difference that increasingly shapes PI prescribing decisions.

Hydroxyzine has no recognized abuse potential. It is not a controlled substance, is not monitored by prescription drug monitoring programs (PDMPs), and does not produce physical dependence or withdrawal syndromes with normal use. It is not habit-forming in the pharmacological sense.

Benzodiazepines carry significant dependence potential. Physical dependence develops with regular use over weeks to months, and abrupt discontinuation can produce a withdrawal syndrome that may include rebound anxiety, tremor, insomnia, and in severe cases, seizures. The DEA Schedule IV classification reflects this recognized abuse and dependence liability. Many state PDMPs require monitoring of BZD prescriptions, and prescribers face regulatory scrutiny around chronic benzodiazepine prescribing.

In the context of a personal injury claim — where patients may be under significant psychological stress, may have pre-existing substance use history, and may be simultaneously receiving opioid analgesics — the risk-benefit calculus around benzodiazepines requires careful consideration.

[!KEY] Hydroxyzine is non-controlled and carries no dependence liability, making it the preferred first-line anxiolytic for many PI pain management physicians — especially in patients simultaneously receiving opioid analgesics, where the combination of opioids and benzodiazepines creates enhanced CNS depression risk.

Use in PI Patients: Clinical Guidelines

Several clinical guidelines and prescribing principles are relevant when choosing between hydroxyzine and benzodiazepines in PI patients.

The FDA black box warning on opioid-benzodiazepine co-prescribing explicitly warns of enhanced CNS depression, respiratory depression, and death when opioids and benzodiazepines are used together. Many PI patients receive both opioid analgesics and anxiolytic/sleep medications simultaneously. This FDA warning has led many PI pain management physicians to prefer hydroxyzine over benzodiazepines for patients already receiving opioids.

Current PTSD treatment guidelines from the VA/DoD and American Psychiatric Association do not recommend benzodiazepines as first-line treatment for PTSD. Evidence suggests BZDs may impair the fear extinction processes that are central to PTSD recovery. Hydroxyzine, while not a primary PTSD treatment, can be used adjunctively for anxiety and sleep in PTSD patients without these concerns.

Insomnia in PI patients is commonly addressed with hydroxyzine 25-50 mg at bedtime as a non-habit-forming sleep aid. Benzodiazepines may be used short-term for acute insomnia but carry dependence risk with prolonged use.

Why Many Pain Management Physicians Now Prefer Hydroxyzine

The shift toward hydroxyzine over benzodiazepines in PI pain management reflects several converging pressures:

• Regulatory environment: Increased PDMP monitoring, DEA scrutiny of controlled substance prescribing, and institutional restrictions on concurrent opioid-BZD prescribing
• Safety profile: No respiratory depression risk, no dependence liability, no withdrawal syndrome
• Opioid co-prescribing: The FDA black box warning on opioid-BZD combinations makes hydroxyzine a safer choice for anxiolysis in the opioid-medicated PI patient
• Evidence: Growing recognition that BZDs may worsen PTSD outcomes over time
• Simplicity: Non-scheduled status means no PDMP query required, no DEA number verification, no refill restrictions

Benzodiazepines continue to have a legitimate clinical role for specific short-term indications — acute procedural anxiety, severe acute anxiety episodes, or situations where rapid and potent anxiolysis is necessary. But for ongoing management of post-injury anxiety and insomnia, hydroxyzine has become the standard of care at many PI-focused practices.

Documentation Value for Psychological Injury Claims

Anxiety, PTSD, and insomnia caused or exacerbated by a personal injury are legitimate components of a plaintiff's damages. Prescriptions for anxiolytic or sleep medications create a documented medication record that supports the psychological injury claim. This documentation value is relevant to both the legal case and the pharmacy lien record.

A prescription for clonazepam or hydroxyzine by a licensed psychiatrist or pain management physician, documented in medical records with a diagnosis tied to the injury, contributes to the overall evidentiary picture of psychological harm. PI attorneys should ensure that the psychological treatment record — including medication prescriptions — is complete and properly linked to the accident in the medical record.

Pharmacy Liens Cover Both Hydroxyzine and Benzodiazepines

Pharmacy lien programs cover both hydroxyzine and Schedule IV benzodiazepines (clonazepam, lorazepam, diazepam, alprazolam) when they are prescribed by a licensed provider for legitimate injury-related psychological care. The prescription must be documented in the medical record and linked to the injury.

For PI patients who cannot afford out-of-pocket prescription costs during the pendency of their case, a pharmacy lien provides access to these medications with no upfront payment required. The lien is satisfied from settlement proceeds at case resolution.

Both medication classes are routinely dispensed through PI pharmacy lien programs, and their inclusion in the patient's prescription record supports the documented narrative of psychological injury following the accident.

Related Resources

• What Is a Pharmacy Lien?
• Low-Dose Naltrexone for Chronic Pain in Personal Injury
• Concussion and TBI Medication Guide
• Spravato Esketamine for Depression After Personal Injury
• Pain Management After a Car Accident